Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457628 | 0.79 | L3MBTL3 (0.49) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL13597027 | 0.79 | DPP4 (0.58) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL3459065 | 0.78 | L3MBTL3 (0.48) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL13597030 | 0.78 | DPP4 (0.56) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL13597034 | 0.78 | DPP4 (0.56) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL13597035 | 0.78 | DPP4 (0.56) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL13597015 | 0.77 | DPP4 (0.63) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL3457813 | 0.77 | L3MBTL3 (0.50) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL3629712 | 0.76 | L3MBTL3 (0.49) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A | |
| SCHEMBL5390527 | 0.76 | L3MBTL3 (0.49) | CYP2D6DPP4L3MBTL1L3MBTL3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | disclosed |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH | 2004-02-12 | — | — | US | disclosed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | CYP2D6 566/4885CYP3A4 1626/4885MAOA 2321/4885 |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | ALK, IDO1, PDXK | CYP2D6 400/4885CYP3A4 989/4885MAOA 1130/4885 |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | ALK, TYMP, ANXA1 | CYP2D6 426/4885CYP3A4 1507/4885MAOA 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.